Results
from drug trials and FDA evaluations can make or break these pharmaceutical
stocks, argues Mr. Elconin in his article.
Investors
in these names better be prepared for the worst possible outcome, although
paying attention to the opening price could be advantageous.
Read more
Benzinga.com small-cap articles: http://www.benzinga.com/news/small-cap
Disclaimer: This
article was posted with the permission of a third-party contributor
and the opinions contained therein do not necessarily reflect
those of Smallcappower. Smallcappower does not endorse any investment
advice provided by these third-party contributors. Please consult
your investment advisor before making any investment decisions.
Ubika
Corporation and its divisions Smallcappower, Ubika Communication and Ubika
Research are not registered with any financial or securities
regulatory authority in Ontario or Canada, and do not provide nor claims
to provide investment advice or recommendations to any visitor of this site or
readers of any content on this site. – See more at: http://www.smallcappower.com/posts/small-cap-power-disclosure#.UoJQkZEq_vw
